US Stock MarketDetailed Quotes
GRFS Grifols
- 6.285
- -0.105-1.64%
Trading Apr 25 15:01 ET
4.27BMarket Cap65.47P/E (TTM)
6.370High6.120Low876.56KVolume6.330Open6.390Pre Close5.45MTurnover0.16%Turnover Ratio65.47P/E (Static)679.09MShares12.15052wk High0.68P/B3.44BFloat Cap5.30052wk Low--Dividend TTM546.96MShs Float24.895Historical High--Div YieldTTM3.91%Amplitude3.642Historical Low6.219Avg Price1Lot Size
Grifols Stock Forum
Sign in to post a comment
ColumnsWall Street Today | Indexes Retreat as Investors Digest Mon. and Tues. Inflation Data
RECAP
Treasury yields jumped on Thursday, and indexes fell after data showed a bigger-than-expected jump in producer prices during February, keeping inflation worries alive. The market reversed from larger declines shortly before closing.
With the preliminary closing numbers, the $S&P 500 Index(.SPX.US$ fell 0.29%, the $Dow Jones Industrial Average(.DJI.US$ fell 0.35%, the $Nasdaq Composite Index(.IXIC.US$...
Treasury yields jumped on Thursday, and indexes fell after data showed a bigger-than-expected jump in producer prices during February, keeping inflation worries alive. The market reversed from larger declines shortly before closing.
With the preliminary closing numbers, the $S&P 500 Index(.SPX.US$ fell 0.29%, the $Dow Jones Industrial Average(.DJI.US$ fell 0.35%, the $Nasdaq Composite Index(.IXIC.US$...
26
1
Gotham City Research has expressed concerns about Grifols' financial reporting and alleged that the company's debt-to-earnings ratio is likely worse than reported. Gotham has also deemed Grifols' shares as 'uninvestable, and likely worthless', a claim that Grifols has rejected.
$Grifols(GRFS.US$ today announced positive topline results from AdFirst phase 3 study confirming the efficacy of fibrinogen concentrate in reducing intraoperative blood loss.
Update
$Grifols(GRFS.US$ Grifols Said Will Take Legal Action Against Gotham City Research For The Significant Damage Caused, Both Financially And Reputationally, To The Company, As Well As To All Its Stakeholders, And For Causing Significant Concern To Its Patients And Donors
The allegations by Gotham City Research have significantly impacted Grifols's stock performance, despite the company's denial of any wrongful accounting or reporting practices. The ongoing investigation by CNMV could further influence the stock's performance.
Might be a buy opportunity?
$Grifols(GRFS.US$ Short Seller Gotham Targets Grifols With Report on Debt, Profit! Causing this massive drop! The company has already responded, And has categorically denied the report as 100% false
1
ColumnsWall Street Today | S&P 500 Closes Just Shy of Record, Up 24% in 2023
RECAP
S&P 500 Closes the Year Up 24%
US stocks slightly pulled back on the last trading day of 2023, trimming the annual gains that were fueled by the meteoric rise of the so-called Magnificent Seven and semiconductors. The 24% rally this year has been driven by the frenzy over artificial intelligence and optimism that the technology could cut costs and boost productivity across Corporate America.
The $S&P 500 Index(.SPX.US$ closed ou...
S&P 500 Closes the Year Up 24%
US stocks slightly pulled back on the last trading day of 2023, trimming the annual gains that were fueled by the meteoric rise of the so-called Magnificent Seven and semiconductors. The 24% rally this year has been driven by the frenzy over artificial intelligence and optimism that the technology could cut costs and boost productivity across Corporate America.
The $S&P 500 Index(.SPX.US$ closed ou...
42
3
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
74023206 : dks impressive